← Leaderboards
Xinna Zhang
Indiana University Indianapolis
$3,467,211
Attributed
$6,660,838
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,660,838 · 4
By mechanism
R01$6,660,838 · 4
Top collaborators
- Xiongbin Lu5 shared
- Mateusz Opyrchal5 shared
- Bryan Paul Schneider3 shared
- Baohua Zhou3 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Xiongbin Lu$8,023,409
- Bryan Paul Schneider$1,500,312
- Mateusz Opyrchal$1,160,437
- Mohamad Azhar$2,100,953
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorCancer BiologyBioinformaticsNeoplastic CellCancer ImmunotherapyT-LymphocyteResearch PersonnelProteinsPublic HealthTumor AntigensAntigen PresentationMediatingOrganoidsCd8-Positive T-LymphocytesImmunologyImmune SystemImmuneImmune Checkpoint BlockadeCytotoxicityCellsGenesImmunotherapyImmune ResponseMammary Neoplasms
Grant awards (13)
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy$585,212
R01 · FY2025 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$501,827
R01 · FY2025 · CA · contact PI
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation$466,898
R01 · FY2025 · CA · contact PI
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy$555,952
R01 · FY2024 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$476,736
R01 · FY2024 · CA · contact PI
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation$443,556
R01 · FY2024 · CA · contact PI
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy$585,212
R01 · FY2023 · CA
Targeting HER2-low breast cancer with 17p loss$524,740
R01 · FY2023 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$491,792
R01 · FY2023 · CA
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation$466,898
R01 · FY2023 · CA · contact PI
Targeting HER2-low breast cancer with 17p loss$524,740
R01 · FY2022 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$501,827
R01 · FY2022 · CA
Targeting HER2-low breast cancer with 17p loss$535,448
R01 · FY2021 · CA